Nuclear Medicine: Page 63

SNMMI: PSMA-PET helps guide prostate cancer therapy
By Wayne Forrest
ANAHEIM, CA - Adding an interim prostate-specific membrane antigen (PSMA)-PET scan during therapy can help guide treatment for patients with prostate cancer, according to a study presented Sunday at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
June 22, 2019
2019 06 23 21 43 9978 2019 06 23 Lu 177 Pmsa Pet 20190623220617
Sofie signs exclusive license for new FAPI radiotracers
By AuntMinnie.com staff writers
Molecular imaging developer Sofie Biosciences has signed an exclusive license agreement with University Hospital Heidelberg in Germany for a new class of radiopharmaceuticals that act as fibroblast activation protein inhibitors (FAPIs).
June 21, 2019
Fluke launches radiation measurement tool
By AuntMinnie.com staff writers
Fluke Biomedical is launching a new survey meter designed to provide radiation measurements with simplified data collection in a single tool for a variety of applications.
June 20, 2019
Shine validates isotope production process
By AuntMinnie.com staff writers
Medical isotope firm Shine Medical Technologies took another step toward medical isotope production with the recently completed validation of its low-enriched uranium process.
June 18, 2019
Jubilant forms new radiopharmaceutical company
By AuntMinnie.com staff writers
Jubilant Pharma has launched Jubilant Radiopharma, a new company that will bring its Jubilant DraxImage Radiopharmacies and Jubilant DraxImage radiopharmaceutical development businesses together under the umbrella of a single radiopharmaceutical brand.
June 18, 2019
Sofie Biosciences acquires Texas radiopharmacy
By AuntMinnie.com staff writers
Molecular imaging developer Sofie Biosciences has acquired Houston Cyclotron Partners, a cyclotron radiopharmacy based in Houston.
June 16, 2019
Blue Earth highlights SNMMI 2019 presentations
By AuntMinnie.com staff writers
Molecular imaging firm Blue Earth Diagnostics is touting 16 presentations involving its Axumin PET radiopharmaceutical and "radiohybrid" prostate-specific membrane antigen imaging agent at next week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
June 13, 2019
Navidea readies public stock offering
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals is planning to raise $6 million in a new public offering of its common stock.
June 13, 2019
ANSTO licensed to fully supply Mo-99
By AuntMinnie.com staff writers
The Australian Nuclear Science and Technology Organisation (ANSTO) has received a license to begin full production of molybdenum-99 (Mo-99) at its new nuclear facility.
June 11, 2019
2019 06 12 21 55 5218 Atom Earth 400
Israeli firm creates unique Mo-99 production process
By AuntMinnie.com staff writers
Researchers at BGN Technologies have developed a method designed to simultaneously produce molybdenum-99 (Mo-99) and other medical isotopes without highly enriched uranium.
June 6, 2019
ANSTO nets funds for nuclear medicine project
By AuntMinnie.com staff writers
The state government of New South Wales in Australia will invest 12.5 million Australian dollars ($8.74 million U.S.) in an initiative to expand and advance nuclear medicine capabilities at the Australian Nuclear Science and Technology Organisation (ANSTO), a major source of radioisotopes.
June 3, 2019
NRC offers options for radiopharmaceutical training
By AuntMinnie.com staff writers
The U.S. Nuclear Regulatory Commission (NRC) has proposed four options relative to current requirements to administer radiopharmaceuticals, including reducing the number of training and experience hours from 700 to 400.
June 3, 2019
2018 12 11 00 02 7009 Atom Nuclear Lab 400
Previous Page
Page 63 of 445
Next Page